Pharmos to Present at the BIO 2005 Business Forum
June 16 2005 - 1:41PM
PR Newswire (US)
Pharmos to Present at the BIO 2005 Business Forum ISELIN, N.J.,
June 16 /PRNewswire-FirstCall/ -- Pharmos Corporation
(NASDAQ:PARSD) today announced that it will present at the BIO 2005
Business Forum on Wednesday, June 22, 2004 at 11:30 am Eastern Time
at the Pennsylvania Convention Center in Philadelphia,
Pennsylvania. Gad Riesenfeld, Ph.D., President and Chief Operating
Officer, will provide an update on the Company's business and
product pipeline. According to the Biotechnology Industry
Organization (BIO), this year's Annual International Convention
will be the world's largest biotechnology gathering, with an
anticipated 18,000 attendees and over 1,500 exhibiting companies
and organizations. Each year the BIO Business Forum provides an
arena for pharmaceutical companies, biotechnology companies,
academic research institutes and investors to meet and explore
mutually beneficial opportunities. Pharmos discovers and develops
novel therapeutics to treat a range of indications, in particular
neurological and inflammatory disorders. The Company's core
proprietary technology platform focuses on discovery and
development of synthetic cannabinoid compounds. Cannabinor, the
lead CB2-selective receptor agonist candidate, is scheduled to
begin Phase I safety studies in the second half of 2005 and, if
successful, enter Phase II testing in pain indications around
yearend or early 2006. From the dextrocannabinoid family, the
neuroprotective drug candidate dexanabinol recently completed a
Phase IIa trial as a preventive agent against post-surgical
cognitive impairment. Other compounds from Pharmos' proprietary
synthetic cannabinoid library are in pre-clinical studies targeting
pain, multiple sclerosis, rheumatoid arthritis and other disorders.
Statements made in this press release related to the business
outlook and future financial performance of the Company, to the
prospective market penetration of its drug products, to the
development and commercialization of the Company's pipeline
products and to the Company's expectations in connection with any
future event, condition, performance or other matter, are
forward-looking and are made pursuant to the safe harbor provisions
of the Securities Litigation Reform Act of 1995. Such statements
involve risks and uncertainties which may cause results to differ
materially from those set forth in these statements. Additional
economic, competitive, governmental, technological, marketing and
other factors identified in Pharmos' filings with the Securities
and Exchange Commission could affect such results. DATASOURCE:
Pharmos Corporation CONTACT: Pharmos U.S. - Gale Smith,
+1-732-452-9556, or Pharmos Israel - Irit Kopelov, +972-8-940-9679;
or Investors - John Quirk, +1-646-536-7029, or Media - Janine
McCargo, +1-646-536-7033, both of The Ruth Group, Inc., for Pharmos
Corporation Web site: http://www.pharmoscorp.com/
Copyright
Pharmos (NASDAQ:PARSD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pharmos (NASDAQ:PARSD)
Historical Stock Chart
From Jul 2023 to Jul 2024